Fredag 27 December | 12:13:13 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-08-28 08:30 Kvartalsrapport 2025-Q2
2025-06-03 N/A Årsstämma
2025-02-28 08:30 Bokslutskommuniké 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning LIPI 0.00 SEK
2024-06-05 - Årsstämma
2024-05-21 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - X-dag ordinarie utdelning LIPI 0.00 SEK
2023-06-08 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2023-01-17 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning LIPI 0.00 SEK
2022-06-02 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-09 - X-dag ordinarie utdelning LIPI 0.00 SEK
2021-06-08 - Årsstämma
2021-06-08 - Extra Bolagsstämma 2021
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-06-12 - X-dag ordinarie utdelning LIPI 0.00 SEK
2020-06-11 - Årsstämma
2020-05-19 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipidor är verksamt inom läkemedelsbranschen. Bolaget arbetar med forskning och utveckling inom preklinisk samt klinisk fas. Störst affärsverksamhet återfinns inom utveckling av läkemedel som vidare används för behandling av diverse hudsjukdomar. Exempel på sjukdomar som behandlas inkluderar exempelvis psoriasis, olika hudinfektioner samt atopisk dermatit. Huvudkontoret ligger i Solna.
2024-05-24 12:21:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Lipidor AB (publ) ("Lipidor" or the "Company") announced on 10 April 2024 that the Board of Directors had resolved on a new issue of shares and warrants ("Units") with preferential rights for the Company's existing shareholders of approximately SEK 58 million (the "Rights Issue"). The Board of Directors' resolution regarding the Rights Issue was approved at an Extraordinary General Meeting held on 21 May 2024. An EU growth prospectus (the "Prospectus"), prepared in connection with the Rights Issue, has today, 24 May 2024, been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the “SFSA”). The Prospectus is available on Lipidors' website (www.lipidor.se) and Carnegie's website (www.carnegie.se).

The Prospectus that Lipidor has prepared in connection with Rights Issue has today been approved by the SFSA. The Prospectus, containing complete terms and instructions and other information about the Rights Issue, is available on Lipidor's website (www.lipidor.se) and Carnegie's website (www.carnegie.se). The Prospectus will also be available at the website of the SFSA (www.fi.se). Application forms will be made available on Lipidor's and Carnegie's websites in connection with the start of the subscription period.

For further information on the Rights Issue, please see the Prospectus.

Summary of the Rights Issue

  • The Rights Issue constitutes of Units and Lipidor will initially receive a maximum of approximately SEK 58.0 million before deduction of costs attributable to the Rights Issue, which are estimated to amount to approximately SEK 8.0 million, of which approximately SEK 4.0 million consists of underwriting compensation given that all underwriters chose cash remuneration. Each Unit consists of four (4) shares and one (1) warrant of series TO 2 (the “Warrants”). Upon full subscription and full exercise of all Warrants within the framework of issued Units, the Company may receive an additional capital contribution of a maximum of approximately SEK 29.0 million.
  • Existing shareholders in Lipidor will on the record date on 27 May 2024, be allocated ten (10) unit rights for each existing share. One (1) unit right entitles to subscription of one (1) Unit in the Rights Issue.
  • In total, a maximum of 289,768,630 Units will be issued. Each Unit consists of four (4) shares and one (1) Warrant. This means that a maximum of 1,159,074,520 new shares and 289,768,630 new Warrants can be issued. The Warrants are intended to be admitted to trading on Nasdaq First North Growth Market.
  • The subscription price has been set at SEK 0.20 per Unit, corresponding to SEK 0.05 per share. The Warrants are issued free of charge.
  • The subscription period runs from and including 29 May 2024 up to and including 12 June 2024.
  • The record date in the Rights Issue is 27 May 2024. The last trading day in the Lipidor share, including the right to receive unit rights, is 23 May 2024. The shares are trading excluding the right to receive unit rights from 24 May 2024.
  • The exercise period for the exercise of Warrants occurs during a period of two (2) weeks from and including the seventh trading day after the Company announces through a press release the study results in the Phase III study or, in the absence of such press release, during the period from and including 15 August 2025 up to and including 29 August 2025. The subscription price upon exercise of the Warrants has been set at SEK 0.10 per share.

Subscription commitments and underwriting agreements

The Rights Issue is covered to approximately 66 percent by subscription undertakings and underwriting undertakings, of which subscription undertakings correspond to approximately 15 percent of the Rights Issue, bottom underwriting undertakings to approximately 34 percent of the Rights issue, intermediate underwriting undertakings approximately 9 percent of the Rights Issue and top underwriting undertakings amount to approximately 8 percent of the Rights Issue. For top underwritings, a compensation of 22 percent of the underwritten amount is to be paid in shares in the Company. For intermediate underwritings, a compensation of 20 percent of the underwritten amount is to be paid in cash or 22 percent of the underwritten amount in shares in the Company. For bottom underwriters, a compensation of 15 percent of the underwritten amount is to be paid in cash or 17 percent of the underwritten amount in shares in the Company. The underwriting compensation in the form of shares is conditional upon the Company's Annual General Meeting 2024 resolving or authorizing the Board of Directors to resolve on the issuance of the shares to the underwriters. No compensation is paid for the subscription undertakings. The subscription undertakings and underwriting undertakings are not secured by bank guarantees, pledges, or similar arrangements.

Time plan for the Rights Issue

29 May – 7 June 2024Trading in unit rights
29 May – 12 June 2024Subscription period
29 May – 24 June 2024Trading in BTU (Paid subscribed unit)
13 June 2024Expected day of publishing the outcome of the Rights Issue

Advisors

Lipidor has mandated Penser by Carnegie, Carnegie Investment Bank AB (publ) and Fredersen Advokatbyrå AB as financial and legal advisors respectively in connection with the Rights Issue.